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Background: Primary adenocarcinoma of the anal 
canal is rare, representing less than 20% of anal canal 
cancers. Given the limited data regarding treatment 
and outcomes, the management of this type of 
cancer is focused on a combined modality therapy 
involving radical surgery and neoadjuvant/adjuvant 
chemoradiotherapy. 
Case study: A 74-year-old woman presented with 
pruritus and anal pain with 6 months duration. MRI 
showed a semi-concentric mass in anal canal posterior 
wall. After an incisional biopsy that revealed an 
adenocarcinoma, the patient underwent neoadjuvant 
chemoradiotherapy followed by laparoscopic 
abdominoperineal resection.
Conclusion: There is limited research into anal 
adenocarcinoma since the rarity of this condition. The 
prognosis of anal adenocarcinoma is poor and the 
management remains controversial. Therapy strategies 
are not well established, however, general agreement 
states that a combined multimodality (combination 
of radical surgical resection and pre or postoperative 
chemoradiotherapy) achieves the best outcome.  
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INTRODUCTION 
Anal canal tumors account for approximately 2% of 
all cancers [1]. It is more common in woman and its 
incidence increases with age [2]. More than 60% of 
tumors of canal anal are histologically squamous cell 
carcinomas. Primary adenocarcinoma of the anal canal 
is a rare malignancy representing less than 20% of all 
anal canal cancers and many of these tumors represent 
rectal cancer with downward spread [1, 3]. The overall 
prognosis is poor. This type of cancer is thought to 
arise from the columnar epithelium of the anal canal 
including the mucosal surface, the anal glands, and the 
lining of fistulous tracts [4, 5]. 
Anal canal adenocarcinoma has a higher prevalence 
in the sixth decade and is similar in both genders. It 
is associated with human papillomavirus infection; 
a history of receptive anal intercourse or sexually 
transmitted disease; a history of cervical, vulvar, 
or vaginal cancer; immunosuppression after solid 
organ transplantation or HIV infection; hematologic 
malignancies; certain autoimmune disorders; and 
smoking. Risk factors also include anal Crohn's disease, 
and chronic fistula-in-ano [6]. 
The management and therapeutic approach of 
this rare type of cancer varies widely. It includes 
local excision, radiotherapy, chemotherapy, 
chemoradiotherapy, sphincter-sparing salvage therapy 
and abdominoperineal excision. Distant metastases 
are more common in adenocarcinoma of the anal 
canal than with other primary anal tumors. Superficial 
inguinal, deep pelvic and abdominal lymph nodes may 
be involved and could limit surgical indication [7]. This 
decision should entail a multidisciplinary discussion 
and clinical course of the patient and lesion.
MATERIAL AND METHODS
Clinical file review at our Hospital Center and 
concordant literature through PubMed/Medline 
database. We used the keywords: “adenocarcinoma”, 
“anal canal”, “abdominoperineal resection” and 
“chemoradiotherapy”.
CASE STUDY
A 74-year-old woman presented with pruritus and 
anal pain with 6 months duration. There were no 
complaints of rectal bleeding during defecation. On 
anoscopic examination, a mass was felt occupying half 
of the circumference (posterior) in the canal anal, with 
extension to anal margin, measuring 3 cm in length. 
Pelvic Magnetic Resonance Imaging (MRI) showed a 
mass lesion with 31x27x24 mm, between 3 and 9 o´clock, 
occupying nearly 180º in the posterior wall of the anal 
canal, involving both internal and external sphincters 
(Figure 1). No signs of extension into ischiorectal or 
ischioanal fossae were evidenced. The rectum did not 
show any tumor. 
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A thoraco-abdominopelvic Computerized Tomography 
(CT) was performed to complete staging and no distant 
metastasis were found. According to 8th edition of the 
AJCC cancer staging manual, the tumor was staged as a 
cT2 N0 M0 (stage IIA). Her hemogram, liver, and kidney 
function tests were within normal limits, with tumor 
markers slightly above normal parameters. The patient 
was submitted to an incisional biopsy that revealed 
to be an adenocarcinoma of the anal canal. After a 
multidisciplinary discussion of the case, it was proposed 
a short course of neoadjuvant chemoradiotherapy in 
order to reduce the mass volume and downstage the 
carcinoma. The regimen planned included capecitabine 
plus 45 Gy in 25 fractions, 5 times/week (1 fraction/
day in pelvis and inguinal sites according to Volumetric 
Modulated Arc Technique). Three months after the end 
of oncologic medical treatment, a re-staging pelvic 
MRI was performed, revealing lesion reduction in the 
posterior wall of rectal-ano transition, with extension 
to the internal but not the external sphincter (Figure 
2). Tumor regression was classified as grade 2 (partial 
response). 
The treatment was, then, followed by laparoscopic 
abdominoperineal resection (APR). Radical surgery 
was carried out with perineum skin resection. The 
histological analysis of the specimen resected indicated 
an adenocarcinoma of the anal canal with invasion 
of the pericolic fat tissue (pT3N0), whereas there was 
no evidence of disease in local lymph nodes. The 
postoperative course was uneventful and the patient 
was discharged on the 8th post-surgery day. Six months 
after, the patient performed a pelvic MRI and a CT scan 
that revealed pelvic recurrence with invasion of the 
vagina and vulva. The patient was proposed for palliative 
chemotherapy with irinotecan plus cetuximab.
DISCUSSION
The anal region is comprised of the anal canal and the 
perianal region. The definition of anal canal cancer, 
based on the 8th edition of the AJCC cancer staging 
manual states them as tumors that develop from 
mucosa that cannot be entirely seen when the buttocks 
is gently pressed[8]. Histologically, the mucosal lining of 
the anal canal is predominantly formed by squamous 
epithelium and its margin is lined with skin. The 
anatomical anal canal begins at the anorectal ring and 
extends to the anal verge. Functionally, is defined by the 
sphincter muscles. The superior border is delineated by 
the palpable upper border of the anal sphincter and 
puborectalis muscles of the anorectal ring with 3-5 
cm in length, and the inferior border starts at the anal 
orifice [9]. This definition is important when radical 
surgical treatment is considered. According to World 
Health Organization, there are 3 types of anal canal 
adenocarcinoma: those whose origin includes the 
upper portion of the anal canal, those that derive from 
anal glands or ducts and those associated with chronic 
anorectal fistulas [10, 11].
Patients diagnosed with anal canal adenocarcinoma 
usually present with advanced disease, distant 
metastasis e, consequently poor survival rates 
comparing to squamous tumors[12, 13]. Clinical 
presentation of anal cancers varies between fistulas, 
abscesses, rectal bleeding, in approximately 45% of 
patients and anal pain or sensation of a rectal mass 
in 30% of the cases. National Comprehensive Cancer 
Network (NCCN) guidelines recommend a careful 
clinical history and physical observation including 
anoscopic examination, palpation of the inguinal 
lymph nodes, fine needle aspiration and/or excisional 
biopsy of enlarged nodes. Before treatment, a PET/CT 
scan and pelvic MRI is needed to provide information 
about tumor staging. Final diagnosis is, only, stablished 
with a biopsy or histological analysis [14]. Most 
adenocarcinomas in the anal canal are rectal carcinomas 
that have spread distally or arise above the dentate line 
through the rectal mucosa. The distinction between an 
anal canal or rectal adenocarcinoma with distal spread 
is very difficult. It involves the pattern of local growth 
and its dual lymphatic drainage, carrying a high risk of 
metastasis in inguinal and femoral lymph nodes than 
adenocarcinomas of the rectum. In our case, the patient 
did not present with enlarged lymph nodes that could 
lead to a worse prognosis due to high risk of distant 
metastasis. Fortunately, the diagnosis was made in an 
early stage (stage IIA).
There are few studies in what concerns anal canal 
adenocarcinoma and it shows that does not exist a well 
stablish treatment protocol [7, 13]. Historically, many 
authors recommended abdominoperineal resection as 
the treatment of choice for this type of cancer. Existing 
retrospective multicentric studies revealed combined 
therapy with chemoradiotherapy and local excision 
as the best choice for these patients, reserving APR as 
a salvage treatment. There is no standard protocol for 
anal canal adenocarcinoma treatment nor European 
guidelines for its management [15]. Nevertheless, 
currently, the advisable therapy for T2/3 N0 M0 
carcinomas is neoadjuvant chemoradiotherapy followed 
by radical surgery, considering adjuvant treatment 
in micrometastases prevention. Chemoradiotherapy 
alone should be reserved for patients not fit to surgery 
or regional metastatic lymphadenopathy. Novel 
techniques such as robotic and microsurgery are 
promising since they enable a precise dissection in the 
pelvis and can minimize morbidity. However, these have 
a wide learning curve and are still under development 
[16].
Therapeutic management of our patient was conducted 
according to existing literature [11]. In our case, a 
multidisciplinary team involving surgeons, oncologists 
and radiologists decided our patients’ treatment should 
associate primary chemoradiotherapy and surgical 
resection. The discussion of all possible options, mainly 
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in initial stages, is essential to guarantee the best quality 
of life. APR was performed without complications. 
Unfortunately, the patient showed pelvic recurrence 
in 6-months follow-up exams. The overall prognosis is 
poor. Adenocarcinoma of the anal canal often requires 
multimodality therapy to achieve better overall survival 
rates (disease-free and 5-year overall survival rates of 
54% and 58%, respectively) [17]. Recurrence rates after 
combined treatment are observed in nearly 20% and 
depend on several factors such as tumor grade [15].
Further research and publication of more clinical cases 
of this rare entity is required for development and 
uniformity of treatment strategies.
CONCLUSION
The prognosis of anal carcinoma is based on the size 
of the primary tumor and the presence of lymph node 
metastases. It is usually poor, and research into this type 
of cancer is limited by its rarity. Therefore, there is little 
information on the optimal management. Relevant 
studies show that a multimodality approach combining 
radical surgical resection and neoadjuvant/adjuvant 
chemoradiotherapy offers the best chance of survival. 
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Figure 1. Pelvic MRI showing concentric lesion in the anal canal before chemo-radiotherapy 
  
Figure 2. Pelvic MRI showing concentric lesion in the anal canal after short course of chemo-radiotherapy
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